ONC1-0013B inhibits AR activity in vitro. A. ONC1-0013B structure. B. LnCAP cells cultured (10% CSS) for 3 days, then treated with tested compounds in presence of 1nM DHT for 1 day. PSA expression plotted as percentage of vehicle control (DMSO; n=2, mean±SEM). Ki values: ± (ONC1-13B), ± (MDV3100), (ARN-509). Mean±SEM from 5 replicate experiments (except ARN-509). C. LnCAP cells cultured (10% CSS) for 3 days, then treated with tested compounds in presence of 1nM DHT for 5 days. Viable cells plotted as percentage of vehicle control (DMSO; n=2, mean±SEM). IC50 values: 30nM (ONC1-13B), 148nM (MDV3100), 240nM (ARN-509). D. Competitive-binding assay vs AR ligand Fluormone™ (PolarScreen™ Androgen Receptor Competitor Assay). IC50 values: 19nM (DHT), (ONC1-13B), (MDV3100).
Each Dragon Pharma steroid is presented with an appropriate description and detailed information along with the view of each blister and each vial of the drug, which has its own unique code, in order to provide a secure and absolute guarantee of the steroids’ quality. In its large catalogue, Dragon Pharma offers more than a hundred different kinds of drugs and this is why the company is recognized as one of the largest in the world, firmly winning the trust of the many bodybuilders. Dragon Pharma has the right to delivery of pharmacological agents to various medical institutions worldwide. The company has a huge number of fairly won awards for the quality and effectiveness of the proposed product, reviews which are positive for the most parts and other factors that indicates the confidence and stable professional level of Dragon Pharma.